Earnings
Home›Earnings›Guidance›Teva’s turnaround lifts branded drug growth, but 2026…
Teva’s turnaround lifts branded drug growth, but 2026 EPS forecast drops
Teva expects 2026 earnings per share of $1.91 to $2.11, down from $2.65 in 2025, citing dilution tied to its Emalex Biosciences acquisition.
Teva Pharmaceutical Industries is seeing its turnaround gain traction as the company shifts sales toward branded drugs, with generic products now making up just over half of overall revenue, according to Yahoo Finance. Branded therapies, including Austedo, Ajovy, and Uzedy, are driving mid-double-digit annual sales growth.
Teva’s management also expects 2026 earnings per share to decline to between $1.91 and $2.11, from $2.65 in 2025, with part of the drop attributed to an initial dilutive effect from Teva’s acquisition of Emalex Biosciences. Starting next year, Teva points to biosimilars and other factors as contributors to a 30% increase in operating profit and adjusted EBITDA.
A further potential catalyst for the next leg of growth is duvakitug, a drug Teva co-developed with Sanofi that is in clinical trials for ulcerative colitis and Crohn’s disease. The company says phase 2b results have been promising and notes that, if phase 3 outcomes are similarly strong, duvakitug could move toward commercialization with previously guided peak annual sales of between $2 billion and $5 billion.